^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    Related drugs:
    2d
    Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study (clinicaltrials.gov)
    P2, N=21, Recruiting, Beijing 302 Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    3d
    A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed (clinicaltrials.gov)
    P3, N=564, Not yet recruiting, ViiV Healthcare
    New P3 trial • Head-to-Head
    4d
    HUB-NEU-2023-01: OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADULT OR LATE-ONSET JUVENILE TYPE C NIEMANN-PICK DISEASE WITH COGNITIVE IMPAIRMENT (2023-505832-36-01)
    P1/2, N=16, Completed, Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL | Active, not recruiting --> Completed
    Trial completion
    |
    efavirenz
    6d
    Analysis of Viral Blips Through Week 192 of the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Studies of Doravirine-Based Regimens in Adults Living With Previously Untreated HIV-1. (PubMed, Open Forum Infect Dis)
    Adults living with untreated HIV-1 were randomized (1:1) to a DOR-containing regimen or comparator (darunavir/ritonavir- or efavirenz-containing), each with 2 nucleos(t)ide reverse transcriptase inhibitors, for 96 weeks (double-blind base), followed by 96 weeks of a DOR-containing regimen (open-label extension). Clinical Trials Registration.  ClinicalTrials.gov NCT02275780, NCT02403674.
    Clinical • P3 data • Journal
    |
    CD4 (CD4 Molecule)
    |
    efavirenz
    7d
    LACRIS: Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, Pomeranian Medical University Szczecin | Not yet recruiting --> Recruiting | Trial completion date: Feb 2026 --> Mar 2027 | Initiation date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> Feb 2027
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Real-world evidence
    9d
    CREATE: Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, International Maternal Pediatric Adolescent AIDS Clinical Trials Group
    New trial
    13d
    The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants. (PubMed, Clin Transl Sci)
    These results suggest that concomitant use of quizartinib and moderate CYP3A inducers should be avoided. Concomitant use of weak CYP3A inducers does not warrant dose adjustment, since the impact on quizartinib exposure is clinically nonrelevant.
    P1 data • PK/PD data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Vanflyta (quizartinib) • efavirenz
    14d
    The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs (clinicaltrials.gov)
    P=N/A, N=0, Approved for marketing, Tibotec Pharmaceuticals, Ireland | N=5178 --> 0
    Enrollment change
    20d
    Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK (clinicaltrials.gov)
    P1, N=60, Recruiting, Indiana University | Trial completion date: Apr 2027 --> Dec 2026 | Trial primary completion date: Apr 2027 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    efavirenz
    24d
    Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK (clinicaltrials.gov)
    P1, N=60, Recruiting, Indiana University | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    efavirenz
    27d
    Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome. (clinicaltrials.gov)
    P1, N=64, Recruiting, Orvida Pharma (formerly Kamari Pharma) | Trial completion date: Feb 2026 --> Nov 2026 | Trial primary completion date: Feb 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    TRPV3 (Transient Receptor Potential Cation Channel Subfamily V Member 3)
    1m
    TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (clinicaltrials.gov)
    P3, N=180, Completed, Janssen Sciences Ireland UC | Active, not recruiting --> Completed
    Trial completion